{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:16:41Z","timestamp":1789917401187,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NIAMS","award":["K24 AR063120"],"award-info":[{"award-number":["K24 AR063120"]}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","award":["none"],"award-info":[{"award-number":["none"]}],"id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1979-7","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T14:05:43Z","timestamp":1567519543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers"],"prefix":"10.1186","volume":"21","author":[{"given":"Vivek","family":"Nagaraja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathie","family":"Spino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Suen","family":"Tsou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn T.","family":"Domsic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lafyatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Frech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia D.","family":"Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"issue":"3","key":"1979_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5301\/jsrd.5000249","volume":"2","author":"J Varga","year":"2017","unstructured":"Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord. 2017;2(3):137\u201352.","journal-title":"J Scleroderma Relat Disord"},{"issue":"1","key":"1979_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.5301\/jsrd.5000232","volume":"2","author":"JR Seibold","year":"2017","unstructured":"Seibold JR, Wigley FM, Schiopu E, Denton CP, Silver RM, Steen VD, et al. Digital ulcers in Ssc treated with oral treprostinil: a randomized, double-blind, placebo-controlled study with open-label follow-up. J Scleroderma Relat Disord. 2017;2(1):42\u20139.","journal-title":"J Scleroderma Relat Disord."},{"issue":"5","key":"1979_CR3","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.semarthrit.2018.08.001","volume":"48","author":"M Hughes","year":"2019","unstructured":"Hughes M, Pauling JD. Exploring the patient experience of digital ulcers in systemic sclerosis. Semin Arthritis Rheum. 2019;48(5):888\u201394.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"1979_CR4","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/acr.22018","volume":"65","author":"T Tingey","year":"2013","unstructured":"Tingey T, Shu J, Smuczek J, Pope J. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken). 2013;65(9):1460\u201371.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"20","key":"1979_CR5","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","volume":"123","author":"JP Stasch","year":"2011","unstructured":"Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123(20):2263\u201373.","journal-title":"Circulation."},{"issue":"4","key":"1979_CR6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1183\/09031936.00039808","volume":"33","author":"F Grimminger","year":"2009","unstructured":"Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, B\u00f6lkow D, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J. 2009;33(4):785\u201392.","journal-title":"Eur Respir J"},{"key":"1979_CR7","doi-asserted-by":"crossref","unstructured":"Coghlan JG, Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017;76(7):1219-27.","DOI":"10.1136\/annrheumdis-2016-210236"},{"issue":"4","key":"1979_CR8","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1183\/09031936.00182909","volume":"36","author":"HA Ghofrani","year":"2010","unstructured":"Ghofrani HA, Hoeper MM, Halank M, Meyer FJ, Staehler G, Behr J, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J. 2010;36(4):792\u20139.","journal-title":"Eur Respir J"},{"issue":"4","key":"1979_CR9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330\u201340.","journal-title":"N Engl J Med"},{"issue":"8","key":"1979_CR10","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1097\/HJH.0b013e32833b558c","volume":"28","author":"Y Sharkovska","year":"2010","unstructured":"Sharkovska Y, Kalk P, Lawrenz B, Godes M, Hoffmann LS, Wellkisch K, et al. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens. 2010;28(8):1666\u201375.","journal-title":"J Hypertens"},{"issue":"8","key":"1979_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043433","volume":"7","author":"M Lang","year":"2012","unstructured":"Lang M, Kojonazarov B, Tian X, Kalymbetov A, Weissmann N, Grimminger F, et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One. 2012;7(8):e43433.","journal-title":"PLoS One"},{"issue":"8","key":"1979_CR12","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1136\/annrheumdis-2014-206809","volume":"74","author":"C Dees","year":"2015","unstructured":"Dees C, Beyer C, Distler A, Soare A, Zhang Y, Palumbo-Zerr K, et al. Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. Ann Rheum Dis. 2015;74(8):1621\u20135.","journal-title":"Ann Rheum Dis"},{"key":"1979_CR13","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.rmed.2016.09.011","volume":"122","author":"O Distler","year":"2017","unstructured":"Distler O, Pope J, Denton C, Allanore Y, Matucci-Cerinic M, de Oliveira Pena J, et al. RISE-SSc: riociguat in diffuse cutaneous systemic sclerosis. Respir Med. 2017;122 Suppl 1:S14\u2013S7.","journal-title":"Respir Med"},{"issue":"6","key":"1979_CR14","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/annrheumdis-2011-200862","volume":"71","author":"C Beyer","year":"2012","unstructured":"Beyer C, Reich N, Schindler SC, Akhmetshina A, Dees C, Tomcik M, et al. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann Rheum Dis. 2012;71(6):1019\u201326.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1979_CR15","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1136\/annrheumdis-2013-204508","volume":"74","author":"C Beyer","year":"2015","unstructured":"Beyer C, Zenzmaier C, Palumbo-Zerr K, Mancuso R, Distler A, Dees C, et al. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGF\u03b2 signalling. Ann Rheum Dis. 2015;74(7):1408\u201316.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1979_CR16","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s40261-018-0698-1","volume":"38","author":"M Huntgeburth","year":"2018","unstructured":"Huntgeburth M, Kie\u00dfling J, Weimann G, Wilberg V, Saleh S, Hunzelmann N, et al. Riociguat for the treatment of Raynaud\u2019s phenomenon: a single-dose, double-blind, randomized, placebo-controlled cross-over pilot study (DIGIT). Clin Drug Investig. 2018;38(11):1061\u20139.","journal-title":"Clin Drug Investig"},{"key":"1979_CR17","volume-title":"Arthritis & rheumatology","author":"D Khanna","year":"2018","unstructured":"Khanna D, Allanore Y, Denton CP, Kuwana M, Matucci-Cerinic M, Pope JE, et al. The effects of riociguat on Raynaud\u2019s phenomenon and digital ulcers in patients with diffuse systemic sclerosis: results from the Phase IIb RISE-SSc Study. In: Arthritis & rheumatology. NJ USA: WILEY 111 RIVER ST, HOBOKEN 07030-5774; 2018."},{"issue":"11","key":"1979_CR18","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2013;65(11):2737\u201347.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1979_CR19","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327\u201339.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1979_CR20","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3899\/jrheum.151437","volume":"43","author":"AA Shah","year":"2016","unstructured":"Shah AA, Schiopu E, Chatterjee S, Csuka ME, Frech T, Goldberg A, et al. The recurrence of digital ulcers in patients with systemic sclerosis after discontinuation of oral treprostinil. J Rheumatol. 2016;43(9):1665\u201371.","journal-title":"J Rheumatol"},{"issue":"4","key":"1979_CR21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.autrev.2014.12.001","volume":"14","author":"I Chora","year":"2015","unstructured":"Chora I, Guiducci S, Manetti M, Romano E, Mazzotta C, Bellando-Randone S, et al. Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis. Autoimmun Rev. 2015;14(4):314\u201322.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"1979_CR22","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/1529-0131(200005)43:5<1085::AID-ANR19>3.0.CO;2-7","volume":"43","author":"GN Andersen","year":"2000","unstructured":"Andersen GN, Caidahl K, Kazzam E, Petersson AS, Waldenstr\u00f6m A, Mincheva-Nilsson L, et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum. 2000;43(5):1085\u201393.","journal-title":"Arthritis Rheum"},{"key":"1979_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.mvr.2016.07.002","volume":"108","author":"Y Yal\u00e7\u0131nkaya","year":"2016","unstructured":"Yal\u00e7\u0131nkaya Y, Ad\u0131n-\u00c7\u0131nar S, Artim-Esen B, Kamal\u0131 S, Pehlivan \u00d6, \u00d6cal L, et al. Capillaroscopic findings and vascular biomarkers in systemic sclerosis: association of low CD40L levels with late scleroderma pattern. Microvasc Res. 2016;108:17\u201321.","journal-title":"Microvasc Res"},{"issue":"6","key":"1979_CR24","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/rheumatology\/kew017","volume":"55","author":"M Cossu","year":"2016","unstructured":"Cossu M, Andracco R, Santaniello A, Marchini M, Severino A, Caronni M, et al. Serum levels of vascular dysfunction markers reflect disease severity and stage in systemic sclerosis patients. Rheumatology (Oxford). 2016;55(6):1112\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"18","key":"1979_CR25","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1001\/jama.2016.5258","volume":"315","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Merkel PA, Krieg T, Le Brun FO, Marr A, et al. Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials. JAMA. 2016;315(18):1975\u201388.","journal-title":"JAMA."},{"issue":"6","key":"1979_CR26","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","volume":"75","author":"E Hachulla","year":"2016","unstructured":"Hachulla E, Hatron PY, Carpentier P, Agard C, Chatelus E, Jego P, et al. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis. 2016;75(6):1009\u201315.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1979-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1979-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1979-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T23:22:03Z","timestamp":1599002523000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1979-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1979"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1979-7","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,3]]},"assertion":[{"value":"10 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Each site\u2019s institutional review board or ethics committee approved the protocol before the study commenced. The study was conducted in accordance with the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Robyn Domsic has worked as a consultant for paid consultant for Eicos Sciences Inc. and Boehringer-Ingelheim. Dr. Robert Lafyatis has received grant support from PRISM Biolab, Regeneron, Elpidera, and Kiniksa. He has served as a consultant for PRISM Biolab, Merck, Bristol Myers Squibb, Biocon, UCB, Formation, Sanofi, and Genentech\/Roche. Dr. Jessica Gordon has received grant support from Corbus Pharmaceuticals and Cumberland Pharmaceuticals. Dr. Dinesh Khanna has served as a consultant for Actelion, Acceleron, BMS, Blade Therapeutics, Boehringer Ingelham, Bayer, ChemomAB, Cytori, Celgene, Curzion, Corbus Pharmaceuticals, CSL Behring, GSK, Genentech, Mitsubishi Tanabe Pharma Development America, Sanofi-Aventis, and UCB. He has stocks in Eicos Sciences, Inc. and has employment with CiviBio Pharma, Inc. He has received grant support from Bristol Myers Squibb, Pfizer, Bayer, and Horizon. The rest of the authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"202"}}